Primary Causes of Death After Permanent Prostate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 433-440

  Bittner, Nathan ^b   Merrick, Gregory S ^a   Galbreath, Robert W ^a   Butler, Wayne M ^a   Wallner, Kent E ^b,c   Allen, Zachariah A ^a   Brammer, Sarah G ^a   Moyad, Mark ^d  

^a WHEELING HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

ADT; Brachytherapy; Primary causes of death; Prostate cancer

Indexed keywords

DECISION MAKING; HEALTH RISKS; MULTIVARIANT ANALYSIS; RANDOM VARIABLES; REGRESSION ANALYSIS;

ADT; BRACHYTHERAPY; HIGH-RISK PATIENTS; PRIMARY CAUSES OF DEATH; PROSTATE CANCER;

RISK ASSESSMENT;

ANTIANDROGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CIGARETTE SMOKING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS, SECOND PRIMARY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SMOKING;

EID: 51449093278     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.013     Document Type: Article

References (34)

1. Cooner W., Mosley B., Rutherford C., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143 (1990) 1146-1152
2. Catalona W., Richie J., Ahmann F., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 151 (1994) 1283-1290
3. Gann P., Hennekens C., and Stampfer M. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289-294
4. Tarone R., Chu K., and Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
5. Stock R., Stone N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
6. Orio P., Wallner K., Merrick G., et al. Dosimetric parameters as predictive factors for biochemical control in patients with high risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys 67 (2007) 342-346
7. Choi S., Wallner K., Merrick G., et al. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 10 (2004) 175-180
8. Merrick G., Butler W., Wallner K., et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68 (2007) 34-40
9. Coebergh J., Janssen-Heijnen M., Post P., et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 52 (1999) 1131-1136
10. Satariano W., Ragland K., and Van Den Eeden S. Cause of death in men diagnosed with prostate carcinoma. Cancer 83 (1998) 1180-1188
11. Post P., Hansen B., Kil P., et al. The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: A population-based study. Br J Urol Int 87 (2001) 821-826
12. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy. Rationale, design and evaluation. Tech Urol 6 (2000) 78-84
13. Merrick G.S., Butler W.M., Wallner K.E., et al. Dosimetry of an extracapsular annulus following permanent prostate brachytherapy. Am J Clin Oncol 30 (2007) 228-233
14. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
15. Wallner K.E., Merrick G.S., True L., et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: Preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 75 (2005) 307-310
16. Merrick G.S., Wallner K.E., Butler W.M., et al. Brachytherapy in men aged ≤ 54 years with clinically localized prostate cancer. Br J Urol 98 (2006) 324-328
17. Stone N., Stock R., and Unger P. Intermediate term biochemical-free progression and local control following 125-I brachytherapy for prostate cancer. J Urol 173 (2005) 803-807
18. Zelefsky M., Wallner K., Ling C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostate cancer. J Clin Oncol 17 (1999) 517-522
19. Zelefsky M., Yamada Y., Hunt M., et al. Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 69 (2007) S178
20. Aus G., Abbou C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
21. Middleton R. The management of clinically localized prostate cancer: Guidelines from the American Urologic Association. CA Cancer J Clin 46 (1996) 249-253
22. De Groot V., Beckerman H., Lankhorst G., et al. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56 (2003) 221-229
23. Hall W., Jani A., Ryu J., et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 22-30
24. Miller T., Balady G., and Fletcher G. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med 19 (1997) 220-229
25. Shepherd J., Cobbe S., Ford I., et al. Prevention of coronary cardiovascular disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
26. Downs J., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
27. Sever P., Dahlof B., Poulter N., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiovascular Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
28. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Cardiovascular Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
29. Fox K. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
30. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 248 (1982) 1465-1477
31. Hjermann I., Velve Byre K., Holme I., et al. Effect of diet and smoking intervention on the incidence of coronary cardiovascular disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 2 (1981) 1303-1310
32. Tsai H., D'Amico A., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
33. Saigal C., Gore J., Krupski T., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
34. Lee W. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 60 (2002) 39-44